Items Tagged ‘pacritinib’

April 27th, 2016

Pacritinib Development in Myelofibrosis Placed on Clinical Hold by the FDA

By

The investigative agent, pacritinib, being evaluated for treatment of myelofibrosis has been placed on full clinical hold by the United States Food and Drug Administration (FDA). All trials including treatment involving pacritinib have been stopped, and the New Drug Application (NDA) to the FDA for pacritinib has been withdrawn.1 Myelofibrosis is a type of blood […]

View full entry

Tags: clinical hold, fda, mpn, myelofibrosis, myeloproliferative neoplasm, Myeloproliferative Neoplasms MPN, NDA, News, pacritinib, withdrawn


March 25th, 2015

Pacritinib May Be Effective against Myelofibrosis without Risk of Myelosuppression

By

The investigational agent pacritinib appears active against myelofibrosis without the risk of myelosuppression, a common side effect of many drugs used to treat myelofibrosis and other myeloproliferative neoplasms (MPN). The developers of pacritinib, CTI BioPharma Corp and Baxter International Inc, announced these findings from a Phase III clinical trial called PERSIST-1. Myelofibrosis is a type […]

View full entry

Tags: blood cancer, mpn, myelofibrosis, myeloproliferative neoplasms, Myeloproliferative Neoplasms MPN, News, pacritinib, PERSIST-1, research